17,261 trials
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Objective Response Rate (ORR) Using RECIST 1.1 — 3 patients
Osteoarthritis
Primary: Change From Baseline in Cartilage Thickness of the cMTFC as Assessed by qMRI on the Target Knee to Week 52 — -0.06791; -0.09693; -0.08545; -0.11562 mm — p=0.165
Pain
Primary: Analgesia: Change From Baseline in Pain Tolerance and Threshold as Measured by the Cold Pressor Test — 9.7; 2.2; 2.1; 1.2 Seconds
Tuberculosis
Primary: New Infection With Mycobacterium Tuberculosis — 19; 18 Participants
Adverse Effect of Radiation Therapy
Primary: Mean Best Corrected Visual Acuity (BCVA) in Patients Treated With Intravitreal Aflibercept Injections for the Management of Radiation Maculopathy. — 0.425; 0.548 Log MAR…
Prostate Cancer Metastatic
Primary: Part B: Progression Free Survival (PFS) — 3.78; 2.83 months
Head Lice Infestation
Primary: Percentage of Hatched Eggs Pre Treatment Relative to Post Treatment — -92.9; -42.3 Percent hatched eggs post versus pre Rx
Major Depressive Disorder
Primary: Change in Investigator-administered MADRS Total Score From Baseline BTRX-246040 and Placebo — -15.0; -13.6 Change in score on a scale from baseline — p=0.5939
Waldenstrom Macroglobulinemia
Primary: Overall Response Rate — 26 Participants
DCIS
Primary: Number of Participants With a Change in Ki-67 Level — 15; 5; 3 Participants — p=0.004
Chronic Lymphocytic Leukemia
Primary: Response to Therapy — 10; 2 Participants
Acute Myeloid Leukemia
Primary: Percentage of Participants With Incidence of Vomiting/Retching From Day 1 Through End of Day 5 — 26.3 percentage of particpants
Carcinoma, Hepatocellular
Primary: Incidence of Dose Limiting Toxicities (DLTs) — 1; 1; 2 Participants
Psoriasis
Primary: Achieving Psoriasis Area and Severity Index (PASI) - 75 at the End of Week 24 — 39.7; 47.2; 44.3; 20.0 percentage of total participants
Covid19
Primary: Recruitment Feasibility — 46 Participants